15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
  • Patent number: 10201587
    Abstract: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 12, 2019
    Assignee: MELINTA THERAPEUTICS, INC.
    Inventors: Eve Neesham-Grenon, Gregory Moeck, Adam Belley, Thomas R. Parr, Jr., Adel Rafai Far
  • Patent number: 10131698
    Abstract: Anti-microbial compositions comprising synthetic peptides for therapeutic use are described. These compositions have found applications in treating human and plant infections.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: November 20, 2018
    Assignee: Council of Scientific & Industrial Research
    Inventors: Shuchishweta Vinay Kendurkar, Durba Sengupta
  • Patent number: 9994858
    Abstract: The present invention relates generally to constructs and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a RNA element that modulates the stability of a transcript corresponding to the transcribable polynucleotide. The present invention provides, inter alia, novel vectors, useful for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: June 12, 2018
    Assignee: Gene Stream PTY LTD
    Inventor: John Daly
  • Patent number: 9975933
    Abstract: A tumor tissue-penetrating peptide specifically binding to neuropilin, or a fusion protein, a small molecule drug, a nanoparticle, or a liposome having the peptide fused therein is provided, as well as a method for preparing the same and a pharmaceutical composition comprising the same for treating, diagnosing, or preventing cancer or angiogenesis-related diseases. The tumor tissue-penetrating peptide is fused to the C-terminus of an anticancer antibody heavy-chain constant region (Fc) and the fused antibody specifically binds to neuropilin, and specifically accumulates in tumor tissue, widens intercellular gaps between tumor vascular endothelial cells, promotes extravasation, increases infiltration within tumor tissue, and shows a remarkably increased in vivo tumor-suppressing activity.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: May 22, 2018
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung Kim, Tae Hwan Shin, Yae Jin Kim, Eun Sil Sung
  • Patent number: 9932384
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 3, 2018
    Assignee: immatics biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 9907837
    Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: March 6, 2018
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9814734
    Abstract: The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (PEG)-derived compound. The liposome of the present invention can be used to treat cancer, especially a cancer chosen from liver cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, pancreas cancer, gastric cancer, and leukemia. The preparation method of the present invention is simple, and the bufalin liposome can increase an effect of antitumor, reduce a toxicity compared with bufalin monomer, and has wide applications.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 14, 2017
    Assignee: The Fourth Military Medical University
    Inventors: Wei Cao, Siwang Wang, Ying Li, Yanhua Xie, Qian Yang
  • Patent number: 9751919
    Abstract: Compositions and methods for the treatment of antibiotic resistant Staphylococcus aureus infections are provided comprising ?-lactam antibiotics, as well as a hyaluronic acid binding peptide. The antibiotics include cephalosporins as well as the ?o?-? lactam antibiotic vancomycin. The methods provide administering the composition to the subject in an amount effective to reduce or eliminate the infection.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: September 5, 2017
    Assignee: EMERGENT BIOSOLUTIONS CANADA INC.
    Inventors: Laura Saward, Xiaobing Han, George G. Zhanel
  • Patent number: 9730984
    Abstract: The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of SEQ ID NO: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a superior effect of treating and preventing rheumatoid arthritis with minimized side effect.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: August 15, 2017
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 9683026
    Abstract: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: June 20, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSLYVANIA
    Inventors: Christopher A. Hunter, Jason Scott Stumhofer
  • Patent number: 9676822
    Abstract: Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ?ID?NO.?28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: June 13, 2017
    Assignee: APIM THERAPEUTICS AS
    Inventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
  • Patent number: 9657072
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: May 23, 2017
    Assignees: Centre National De La Recherche Scientifique, Immupharma France SA
    Inventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
  • Patent number: 9644001
    Abstract: A vector that includes a cell-penetrating peptide linked to a therapeutic agent. The therapeutic agent can be a cytotoxic agent, an anti-viral agent, an anti-bacterial agent, or an anti-parasitic agent.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 9, 2017
    Assignees: Universite Pierre Et Marie Curie (Paris 6), Institut Curie
    Inventors: Angelita Rebollo Garcia, Fariba Nemati, Didier Decaudin, Jeronimo Bravo Sicilia, Jesus Maria Fominaya Gutierrez
  • Patent number: 9617302
    Abstract: The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 11, 2017
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Tur-Fu Huang, Chien-Hsin Chang, Ching-Hu Chung
  • Patent number: 9617606
    Abstract: The present invention provides an oligonucleotide for HIV detection including a base sequence which is at least 80% identical to a base sequence composed of 10 or more continuous bases in a base sequence represented by SEQ ID NO. 1 or 6, and an HIV detection kit and an HIV detection method that uses the oligonucleotide for HIV detection.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 11, 2017
    Assignee: Japan Science and Technology Agency
    Inventors: Taketoshi Mizutani, Aya Ishizaka
  • Patent number: 9597362
    Abstract: The disclosure relates to the live cultures of probiotic bacteria to treat infectious diseases in humans and animals. Food-grade or non-pathogenic cultures are used to treat localised infections.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: March 21, 2017
    Assignees: TEAGASC, THE AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY, UNIVERSITY COLLEGE, CORK-NATIONAL UNIVERSITY OF IRELAND
    Inventors: Paul Ross, Colin Hill, William Meaney
  • Patent number: 9580472
    Abstract: Anti-microbial peptides and methods of use are provided.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: February 28, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Guangshun Wang
  • Patent number: 9572900
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 21, 2017
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9567368
    Abstract: Peptides that increase melanin synthesis are provided. These peptides include pentapeptides YSSWY (SEQ ID NO: 1), YRSRK (SEQ ID NO: 2), and their variants. The peptides may activate the enzymatic activity of tyrosinase to increase melanin synthesis. The pharmaceutical, cosmetic, and other compositions including the peptides are also provided. The methods of increasing melanin production in epidermis of a subject are provided where the methods include administering compositions comprising an amount of one or more peptides effective to increase the melanin production. The methods also include treating vitiligo or other hypopigmentation disorders with compositions including one or more peptides.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: February 14, 2017
    Assignee: Escape Therapeutics, Inc.
    Inventors: Basil M. Hantash, Anan Abu Ubeid
  • Patent number: 9562066
    Abstract: The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: February 7, 2017
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventor: David J. Hackam
  • Patent number: 9562075
    Abstract: The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: February 7, 2017
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
  • Patent number: 9482676
    Abstract: The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 1, 2016
    Assignees: SAGA UNIVERSITY, KURUME UNIVERSITY
    Inventors: Kenji Izuhara, Shoichiro Ohta, Hiroshi Shiraishi, Hisamichi Aizawa, Tomoaki Hoshino, Masaki Okamoto
  • Patent number: 9476033
    Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: October 25, 2016
    Assignee: The University of Maryland, College Park
    Inventors: Siba K. Samal, Zhuhui Huang
  • Patent number: 9464112
    Abstract: Provided are small peptide fragments derived from the NF-?B p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-?B inhibitory activity, through controlling the transcription-activation of NF-?B. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-?B, and also inhibit the transmigration of leukocytes, thereby exhibiting an anti-inflammatory activity. Especially, the peptides have excellent inhibitory activities against dermatitis and skin aging. And also, the peptides inhibit base membrane invasion of cancer cells, thereby exhibiting an inhibitory activity against the growth and/or metastasis of cancer cells.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 11, 2016
    Assignee: KNU-INDUSTRY COOPERATION FOUNDATION
    Inventors: Jang-Hee Hahn, Chang-Seo Park, In-Young Ko, Byong-Ik Chun, Byoung-Chul Kim
  • Patent number: 9447145
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: September 20, 2016
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Patent number: 9433667
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: September 6, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black
  • Patent number: 9314516
    Abstract: What is described is a novel genetic screen, involving recombinant technology and class I antigen cross-presentation, to search for supraoptimal superagonists of the 27L MART-1 mutant selecting for single amino acid substitution mutants of 27L that activate human antigen-specific CTL clones recognizing the wild-type MART-126-35 epitope. Three novel mutant epitopes are identified with superagonist properties that are functionally superior to 27L. The ability of a given analog to act as superagonist varies among patients. Also described is the use of methods to establish panels of potential superagonist APLs to individualize tumor peptide vaccines among patients. The methodology is replicated to identify APL to NY-ESO-1157-165 and NY-ESO-1157-170 tumor epitopes. A general method is described that is useful to produce a tumor vaccine to any tumor epitope.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: April 19, 2016
    Inventors: Cassian Yee, Yongqing Li, C. Siddiq Abdul-Alim
  • Patent number: 9273111
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterized by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: March 1, 2016
    Assignees: Universite de Lorraine, Bristol-Myers Squibb
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini
  • Patent number: 9260476
    Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: February 16, 2016
    Assignee: The Research Foundation for The State University of New York
    Inventor: Matthew David Disney
  • Patent number: 9221881
    Abstract: The invention relates to new peptides and to their use in the diagnosis of celiac disease.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: December 29, 2015
    Assignee: Charité-Universitätsmedizin Berlin
    Inventor: Karl Skriner
  • Patent number: 9206234
    Abstract: The invention provides a method of making a peptide comprising the amino acid sequence WDLYFEIVW (SEQ ID NO: 322) or a variant thereof, the method comprising (a) coupling the C-terminal amino acid of the peptide to a cleavable linking moiety bonded to a solid phase support material, wherein the alpha-amino group of the C-terminal amino acid that is to be coupled bears an Fmoc protecting group; (b) removing the Fmoc protecting group from the C-terminal amino acid that is coupled to the linking moiety; (c) successively coupling Fmoc-protected amino acids to the C-terminal amino acid, with attendant cleavage of the Fmoc protecting group prior to each successive amino acid addition, thereby producing an amino acid sequence bearing side chain protecting groups; and (d) removing the side chain protecting groups and cleaving the peptide from the solid phase support material.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: December 8, 2015
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Patent number: 9193765
    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: November 24, 2015
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa
  • Patent number: 9156906
    Abstract: In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 13, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Alessandra Franco
  • Patent number: 9096689
    Abstract: The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 4, 2015
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Olga Volpert, Yelena Mirochnik
  • Patent number: 9072773
    Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: July 7, 2015
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Patent number: 9072709
    Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: July 7, 2015
    Assignees: The Regents of the University of California, The United States of America Represented by The Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa Murray, Jeffrey Wang, Keyvan Behnam
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150147346
    Abstract: The present invention provides methods of diagnosing, treating, and preventing prion and neurodegenerative disorders including vaccines against prion diseases and neurodegenerative disorders.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Samuel Bogoch, Elenore S. Bogoch, Anne-Elenore Bogoch Borsanyi, Samuel Winston Bogoch
  • Publication number: 20150148302
    Abstract: The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.
    Type: Application
    Filed: March 7, 2014
    Publication date: May 28, 2015
    Applicant: The Trustees of Columbia University in the city of New York
    Inventor: Carol M. Troy
  • Patent number: 9040662
    Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 26, 2015
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION
    Inventors: Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
  • Publication number: 20150139955
    Abstract: A peptide dimer comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1 and the peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4 are bound through a disulfide bond between a cysteine residue of each peptide is used as an active ingredient of an agent for promoting proliferation of one or more bacterium selected from the group consisting of Bifidobacterium infantis and Bifidobacterium breve.
    Type: Application
    Filed: August 24, 2012
    Publication date: May 21, 2015
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Hirotsugu Oda, Koji Yamauchi, Takumi Sato, Kanetada Shimizu
  • Publication number: 20150140001
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clecl4a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clecl4a as an epitope for an antibody suppressive of angiogenesis.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Publication number: 20150141274
    Abstract: Disclosed herein are methods, compositions, and kits for isolating actively translated mRNA from heterogeneous cell populations. Also disclosed herein are methods, compositions, and kits for identifying cell types that respond to stimuli in heterogeneous cell populations.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 21, 2015
    Inventors: Jeffrey M. Friedman, Zachary A. Knight, Keith Tan, Kivan Birsoy
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150132395
    Abstract: The invention relates to nanoemulsions useful for analytical techniques and delivery of cargoes such as pharmaceutically active agents. In particular, the invention relates to nanoemulsions comprising an oil phase dispersed in an aqueous phase and at least two peptide surfactants adsorbed at the liquid-liquid interface, one peptide surfactant comprising a short peptide sequence having ?-helical propensity and at least one second polypeptide surfactant comprising at least two peptide sequences having ?-helical propensity linked by a linking sequence of 3 to 11 amino acid residues. Optionally the at least one second polypeptide surfactant comprises at least one pharmacokinetic modifying agent and/or a targeting agent. Furthermore, the nanoemulsion may further comprise a cargo such as a pharmaceutically active agent.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 14, 2015
    Inventors: Anton Peter Jacob Middelberg, Bijun Zeng
  • Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150133385
    Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.
    Type: Application
    Filed: October 18, 2012
    Publication date: May 14, 2015
    Inventors: Richard Béliveau, Jonathan Michaud-Levesque, Krishna G. Peri, Abdelkrim Habi, Nathalie Bousquet-Gagnon
  • Publication number: 20150132235
    Abstract: A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C92, H139, N35, O28, S6 acetate salt (molar mass 2376 g/mol.). Also, the use of the composition to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.
    Type: Application
    Filed: April 15, 2013
    Publication date: May 14, 2015
    Applicant: ACTIVEN
    Inventors: Reto Stocklin, Jean-Marc Le Doussal, Louis Lamy, Bethsabee Coutaz
  • Publication number: 20150133393
    Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 14, 2015
    Inventors: Jean-Marc Combette, Catherine Deloche